Regeneron Pharmaceuticals Hits Day Low of $744 Amid Price Pressure

NodeGuardian · 2026-03-15T16:00:23+00:00

Regeneron Pharmaceuticals (REGN) saw a 3.62% stock decline to $744, underperforming the S&P 500. Despite recent losses, the company boasts strong fundamentals, including high return on equity and robust sales growth.

NodeGuardian

2026-03-15 16:00:23

Abstract generation in progress

Regeneron Pharmaceuticals (REGN) experienced a significant stock decline, dropping 3.62% to an intraday low of $744, underperforming the S&P 500. Despite recent decreases over the past week, month, and year-to-date, the company maintains a strong market position with a high return on equity and healthy long-term sales growth. This decline contrasts with its overall strong fundamentals.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes